Last reviewed · How we verify
NCT05981378: PATHO-NAT
Genomic Approaches to Dissect Human Host-pathogen Interactions in the Amazonian Rainforest
trial in Host-Pathogen Interactions in 300 participants. Not yet recruiting.
20 November 2024
Quick facts
| Lead sponsor | Universidad Peruana Cayetano Heredia |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 2 August 2024 |
| Primary completion | 20 November 2024 |
| Estimated completion | 30 January 2025 |
Conditions studied
- Host-Pathogen Interactions — all drugs for Host-Pathogen Interactions →
Sponsor
Universidad Peruana Cayetano Heredia — full company profile →
Who can join
Adults 18 to 65, any sex, with Host-Pathogen Interactions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study, aims to characterize with a multi-omic approach, the impact of host genetics and the pathogenic environment on immune response variation in Native Amazonians in comparison with Mestizo Amazonian, a severely underrepresented population in genomic studies. Various samples will be taken from the participants, including blood, urine, saliva, etc. From the blood sample, peripheral blood mononuclear cells will be obtained and will give us information about the differences between immune response variation of Amazonian population. From the other samples we will be able to obtain additional information on the risk factors related to the difference in the immune response of the participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05981378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Universidad Peruana Cayetano Heredia trials
Trials by the same sponsor.
- NCT06367361 — One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis · Phase 2 · not yet recruiting
- NCT06989502 — Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries · NA · not yet recruiting
- NCT06565507 — Oxfendazole in Mild Parenchymal Brain Cysticercosis · Phase 2, PHASE3 · not yet recruiting
- NCT06500013 — WhatsApp Intervention to Assess the Effect of Messages in Adherence to Antiretrovirals in Young People With HIV in Peru · NA · active not recruiting
- NCT05524987 — Addressing HyperteNsion and Diabetes Through Community-Engaged Systems in Puno, Peru (ANDES Study) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05981378 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Peruana Cayetano Heredia
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05981378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing